Renalytix/RNLX

$0.80

0.63%
-
1D1W1MYTD1YMAX

About Renalytix

Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Ticker

RNLX

Sector

Healthcare

Trading on

NASDAQ

Industry

Software & Programming

CEO

-

Employees

102

Headquarters

London, United Kingdom

Renalytix Metrics

BasicAdvanced
$47.09M
Market cap
-
P/E ratio
-$0.91
EPS
2.96
Beta
-
Dividend rate
$47.09M
2.96181
$4.04
$0.24
1.88M
0.593
-9.14%
-199.59%
-9,009.47%
-609.73%
19.538
-36.65%
20.51%

What the Analysts think about Renalytix

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 2 analysts.
400% upside
High $5.00
Low $3.00
$0.80
Current price
$4.00
Average price target

Renalytix Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,200% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$700K
75%
Net income
$-8.4M
-16.83%
Profit margin
-1,200%
-52.48%

Renalytix Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 100%
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$0.28
-$0.24
-$0.22
-$0.18
-
Expected
-$0.11
-$0.13
-$0.10
-$0.09
-$0.08
Surprise
154.55%
89.47%
120%
100%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Renalytix stock?

Renalytix (RNLX) has a market cap of $47.09M as of April 22, 2024.

What is the P/E ratio for Renalytix stock?

The price to earnings (P/E) ratio for Renalytix (RNLX) stock is 0 as of April 22, 2024.

Does Renalytix stock pay dividends?

No, Renalytix (RNLX) stock does not pay dividends to its shareholders as of April 22, 2024.

When is the next Renalytix dividend payment date?

Renalytix (RNLX) stock does not pay dividends to its shareholders.

What is the beta indicator for Renalytix?

Renalytix (RNLX) has a beta rating of 2.96. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Renalytix stock price target?

The target price for Renalytix (RNLX) stock is $4, which is 400% above the current price of $0.8. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Renalytix stock

Buy or sell Renalytix stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing